Jeffrey Baron

7PUBLICATIONS
32CO-AUTHORS
Predictive and prognostic markersHaematological tumoursHaematologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 20, 2026
Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

|May 30, 2026
Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.

|Mar 26, 2025
Multicenter Retrospective Evaluation of Treatment for High-Risk Acute Promyelocytic Leukemia: Real-World Outcomes From the HERO Consortium.

Lydia L Benitez, Kayleigh R Marx, Caitlin R Rausch

|Dec 27, 2024
Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.

Jeffrey Baron, Daniel Appiah, Mark G Faber

|Jul 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.

Joseph Pidala, Shernan G Holtan, Kelly Walton

Pageof 2

Frequent Collaborators

2 joint publications

Amanda Przespolewski

2 joint publications

Bernard L Marini

2 joint publications

Elizabeth A Griffiths

2 joint publications

Caitlin Rausch